Trial Profile
A Double-Blind, Placebo-Controlled Trial of Combined Cytidine- and Creatine-Containing Drug and Dietary Supplement in the Treatment of the Bipolar Depression
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Creatine monohydrate (Primary) ; Cytidine (Primary) ; Valproic acid (Primary)
- Indications Bipolar depression
- Focus Therapeutic Use
- 09 Feb 2018 Planned End Date changed from 1 Dec 2013 to 30 Apr 2017.
- 09 Feb 2018 Planned primary completion date changed from 1 Dec 2013 to 30 Apr 2017.
- 09 Feb 2018 Status changed from recruiting to withdrawn prior to enrolment due to cancellation of research project.